The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2022 | The role of MRD in decision making in patients with NHL
In this video, Meryl D. Colton, MD, University of Colorado, Denver, CO, briefly discusses the role of measurable residual disease (MRD) in treatment decisions and minimizing late toxicities in patients with non-Hodgkin lymphoma (NHL). Dr Colton highlights the importance of using MRD in prognosis and when detecting early refractoriness or relapse, as well as its role in the future use of CAR-T therapy. This interview took place at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting in Chicago, IL.
